Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1] Group 1: Investigation Details - The investigation is prompted by a press release from Alvotech on November 2, 2025, regarding the status of its Biologics License Application (BLA) for AVT05, which received a complete response letter (CRL) from the FDA [3] - The CRL indicated that certain deficiencies identified during the FDA's pre-license inspection of Alvotech's Reykjavik manufacturing facility must be resolved before the BLA can be approved [3] - Following the announcement, Alvotech's stock price dropped by 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3] Group 2: Class Action Information - Shareholders who purchased Alvotech securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2] - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4]